IceCure Medical, a developer of cryoablation technology for tumor treatment, announced it will publish its financial and operational results for the nine months ending September 30, 2026, on November 18 before Nasdaq opens. The company will also host a conference call to discuss these results and corporate updates. IceCure's ProSense® system is notable for being FDA-cleared for local breast cancer treatment in certain patients. Investors can access the live webcast or recording via provided links.
IceCure Medical's upcoming Q3 2026 financial results provide context for readers interested in health-related stocks. As of Nov 11, 2026 20:11 WIB, 69 of 150 priced Health-sector US stocks on Pluang rose while 74 fell. Notable movers include Butterfly Network Inc. at USD 6.70 with a 2.92% increase, MiniMed Group Inc. at USD 17.81 up 2.59%, and BioNano Genomics Inc. at USD 1.20 down 2.44% with 100% buy order activity.
The global telehealth market, valued at $77.4 billion in 2025, is projected to expand to $187.5 billion by 2033, driven by increasing patient demand for virtual care and advances in AI, remote monitoring, and wearable health devices. Companies like R...
The Portnoy Law Firm is investigating Arbor Realty Trust, Inc. for possible securities fraud following the company's October 30, 2026 announcement to suspend its quarterly cash dividend due to financial challenges. This announcement caused Arbor's st...
RUM Group Inc. reported a record quarterly revenue of $96.6 million for Q3 2026, a 290% increase year-over-year, surpassing expectations. Despite this, earnings per share were -$0.19, missing the estimate of -$0.11. The company achieved its first pro...
Richtech Robotics announced its Intelligent Cleaning System at ISSA Show North America 2026, which integrates autonomous cleaning robots with CCTV cameras to enable proactive, targeted cleaning. This system uses real-time data to optimize cleaning ta...
The 2026 Vertex CompOps™ Index reveals that just 16% of enterprises regularly discuss indirect tax at the board level, while 43% only address it when issues arise. Companies with board-level focus on indirect tax are four times less likely to have er...
